At the opening public session of the Instand-NGS4P Consortium Meeting, Ivo Gut (CNAG-CRG, Spain) and Sir Mark Caulfield (Genomics England) gave a
Coordinator Kurt Zatloukal presents the Request for Tender to over 80 interested participants from 14 different countriesThe Request for Tender to develop
The 65 month Instand-NGS4P PCP project concludes by announcing the successful completion of the final testing phase, and proudly invites you to view the innovations made towards ensuring integrated and standardized NGS workflows for the benefit of cancer patients. View the Results of the pre-commercial procurement View the advancements in standardization of NGS workflows
BRUSSELS – [May 26, 2025] – A pivotal event, hosted on Tuesday, May 20, 2025 at the European Parliament by MEP Vlad (Vasile) Voiculescu (RENEW/Romania) and endorsed by MEP Letizia Moratti (EPP/Italy) and former MEP Paul Ruebig, convened leading policymakers, EU Commission officials, scientists, clinicians, and patient representatives to address the urgent need for integrating
Follow the livestream of our event at the European Parliament via our website! High Level Seminar – Integrated and Standardized NGS Workflows for Personalised Therapy We welcome you to join us remotely to listen to the high level discussions between our expert speakers and panellists, as well as the input from the participants. Please get
CEN/TS 17981-1:2023, In vitro diagnostic Next Generation Sequencing (NGS) workflows — Part 1: Human DNA examination CEN/TS 17981-2:2023, In vitro diagnostic Next Generation Sequencing (NGS) workflows — Part 2: Human RNA examination These 2 CEN/TS documents, developed by CEN/TC 140 WG3 in the context of the Instand-NGS4P project, cover all the steps needed to obtain successful and reliable sequence
High-level Conference: Tackling the implementation gap for the uptake of NGS and advanced molecular diagnostics into healthcare systems: The Role of Pathology and Medical Laboratories Organised as an ECP satellite event by the European Alliance for Personalized Medicine, this conference will present and discuss ways to improve patients´ benefits from advanced molecular diagnostics including NGS.
We are pleased to announce that of the ten Contractors that successfully completed Phase 2, eight have now been awarded Specific Contracts for Phase 3 to complete testing and integration of the innovative NGS workflows. Phase 3 commenced in April 2024 and will end in May 2025. Further details can be found under Phase 3
The Instand NGS4P project consortium and Contractors will meet in Graz on the 9th of April 2024 to present the project and the developed Solutions at a public meeting. Two keynote speakers, Jean-Yves Blay (from Instand-NGS4P Partner CLB) and Matthias Schwab (IKP) will give talks on the challenges of precision medicine of cancer and on
The canSERV Consortium announces its first Challenge-Call on "Advancing Personalised Oncology".Cancer Researchers in, and outside the EU are invited to apply for free access to cutting-edge transnational services with an indicative overall budget of EUR 500,000. The aim of this call is to accelerate knowledge gain in personalised oncology with specific emphasis on multi-level data-based
This year's meeting of the Instand NGS4P project consortium and contractors was held in Vienna, Austria, as a hybrid meeting combining both face-to-face and online formats. The two-day event provided a valuable platform for contractors to present their innovative prototypes to consortium members present from across Europe.In addition, the clinical project partners also had the
Instand-NGS4P Beneficiary, OECI - the Organisation of European Cancer Institutes - has dedicated an entire Newsletter to the Instand-NGS4P project. The Newsletter describes the aims of the project, and progress made to date. This is an important dissemination tool, with the OECI Audience comprising 1300 contacts including: OECI Membership; Cancer Organisations and & relevant cancer